Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Multiple Indications
Last updated August 26, 2025
Status:
Concluded without agreement
Manufacturer:
Alexion Pharma GmbH
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH)
Last updated August 26, 2025
Status:
Concluded with an LOI
Manufacturer:
Apotex Inc.
Indication:
Multiple Indications
Last updated August 19, 2025
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Multiple Indications
Last updated August 19, 2025
Status:
Concluded with an LOI
Manufacturer:
Sandoz Canada Inc.
Indication:
Multiple Indications
Last updated August 19, 2025
Status:
Concluded with an LOI
Manufacturer:
Biocon Biologics Canada Inc.
Indication:
Multiple Indications
Last updated August 19, 2025
Status:
Concluded with an LOI
Manufacturer:
Organon Canada Inc.
Indication:
Multiple Indications
Last updated August 19, 2025
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.
Last updated August 13, 2025
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Primary hypercholesterolemia
Last updated August 13, 2025
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Primary hypercholesterolemia (non-familial and heterozygous familial)
Last updated August 13, 2025